Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Investing.com - BMO Capital reiterated its Outperform rating and $28.00 price target on Acadia Pharmaceuticals (NASDAQ:ACAD), currently trading at $22.50 with a market capitalization of $3.77 billion, following the company’s research and development event. According to InvestingPro, the company maintains a "GREAT" financial health score of 3.7.
The R&D event showcased Acadia’s development portfolio, which extends beyond its commercially approved products Nuplazid and Daybue. BMO Capital noted that investors have primarily focused on growth dynamics for Acadia’s approved products rather than its pipeline potential.
BMO Capital highlighted that the assets discussed during the R&D day could potentially provide an additional $12 billion in unadjusted revenues for the company. This represents significant growth potential beyond Acadia’s current commercial offerings.
Among the pipeline candidates, BMO Capital expressed particular optimism about ACP-211, citing the validated success of Spravato in major depressive disorder (MDD) as a comparable treatment. This suggests confidence in the clinical pathway for this development program.
The firm also mentioned other assets in development, including ACP-711 for essential tremor (ET), which it characterized as higher-risk opportunities with significant upside potential that investors "may still be discounting."
In other recent news, Acadia Pharmaceuticals has been the focus of several analyst evaluations following its inaugural R&D Day. The company anticipates generating over $1 billion in net sales this year from its commercial portfolio, which includes Nuplazid for Parkinson’s disease psychosis and Daybue for Rett syndrome. Acadia plans to initiate seven late-stage clinical studies by 2026, with five study readouts expected through 2027. Canaccord Genuity reiterated a Buy rating with a $32.00 price target, emphasizing the undervaluation of Acadia’s pipeline, which could potentially reach $12 billion in unadjusted peak sales. Goldman Sachs maintained a Sell rating with a $15.00 price target, while expressing positivity about the ACP-204 trials for Alzheimer’s and Lewy Body dementia psychosis. Citizens JMP reaffirmed a Market Outperform rating and a $37.00 price target, highlighting Acadia’s broad pipeline and expected revenue growth. RBC Capital raised its price target to $38.00 from $26.00, citing a strong commercial stage and potential for sustained cash flow. These developments indicate a mixture of optimism and caution among analysts regarding Acadia’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.